RETAIN-2: A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer (clinicaltrials.gov) - Sep 22, 2026 - P2 | N=81 | Active, not recruiting | Sponsor: Fox Chase Cancer Center | Trial primary completion date: May 2026 ➔ May 2027
Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
|